Loading…
Lakewood-Amedex Biotherapeutics, Inc. is projected to rise to $1.09 by 2027, a +48% move from its current price of $0.7333.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.6439 | $0.734 | $0.8366 | +0.09% |
| May 30 | $0.6105 | $0.7346 | $0.884 | +0.18% |
| May 31 | $0.5862 | $0.7353 | $0.9224 | +0.27% |
| Jun 1 | $0.5665 | $0.736 | $0.9561 | +0.36% |
| Jun 2 | $0.5498 | $0.7366 | $0.987 | +0.45% |
| Jun 3 | $0.5351 | $0.7373 | $1.02 | +0.55% |
| Jun 4 | $0.522 | $0.738 | $1.04 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.522 | $0.738 | $1.04 | +0.64% |
| Week 2 | $0.4552 | $0.7427 | $1.21 | +1.28% |
| Week 3 | $0.4103 | $0.7474 | $1.36 | +1.92% |
| Week 4 | $0.3764 | $0.7522 | $1.50 | +2.57% |
| Week 5 | $0.349 | $0.757 | $1.64 | +3.23% |
| Week 6 | $0.3262 | $0.7618 | $1.78 | +3.89% |
| Week 7 | $0.3068 | $0.7667 | $1.92 | +4.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents that fight infections by disrupting microbial membranes.
It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers.
The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
LABT is a healthcare stock with a small-cap profile. It currently trades at $0.7066 and has a market cap of $10.12M, ranking 5151 by size.
A major floor 3.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 1079.6% above — a clean break opens room to run.
A major ceiling 1079.6% above — clearing it would confirm fresh momentum.
Key LABT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.71 | $0.7333 | $1.43 | 0% | Neutral | |
| $0.7007 | $1.09 | $1.82 | +48% | Bullish | |
| $0.6098 | $1.05 | $1.90 | +43% | Bullish | |
| $0.513 | $0.9654 | $1.87 | +32% | Bullish | |
| $0.4456 | $0.9145 | $1.86 | +25% | Bullish | |
| $0.4087 | $0.9083 | $1.93 | +24% | Bullish | |
| $0.3914 | $0.8698 | $1.92 | +19% | Neutral | |
| $0.556 | $1.24 | $2.82 | +69% | Bullish | |
| $0.6529 | $1.45 | $3.34 | +98% | Bullish | |
| $0.5545 | $1.23 | $2.83 | +68% | Bullish | |
| $0.7659 | $1.70 | $3.91 | +132% | Bullish | |
| $1.08 | $2.40 | $5.51 | +227% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.71 | $0.7333 | $0.8872 | +0.00% |
| June 2026 | $0.6509 | $0.7979 | $1.02 | +8.81% |
| July 2026 | $0.6332 | $0.7966 | $1.06 | -0.17% |
| August 2026 | $0.6035 | $0.7751 | $1.06 | -2.70% |
| September 2026 | $0.6505 | $0.85 | $1.19 | +9.67% |
| October 2026 | $0.7079 | $0.9401 | $1.34 | +10.59% |
| November 2026 | $0.7015 | $0.9449 | $1.37 | +0.52% |
| December 2026 | $0.7085 | $0.9677 | $1.43 | +2.41% |
Click any year to see its month-by-month LABT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LABT is projected to trade between $0.71 and $1.43, averaging $0.7333 — a potential gain of 0% from today's $0.7333. Price action looks broadly range-bound.
Lakewood-Amedex Biotherapeutics, Inc.'s 2027 outlook centres on $1.09, within a $0.7007 to $1.82 range. That is up +48% on the projected 2026 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, LABT could reach as high as $1.90, with a base case around $1.05 and support toward $0.6098 — roughly +43% from $0.7333. Momentum favours further upside here.
Expect LABT to range from $0.513 to $1.87 through 2029. The $0.9654 average target implies a +32% move from current prices. That is -8% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The LABT price prediction for 2030 points to an average of $0.9145 (low $0.4456, high $1.86) — a potential gain of +25% on today's $0.7333. Momentum favours further upside here.
In 2031, LABT is projected to trade between $0.4087 and $1.93, averaging $0.9083 — a potential gain of +24% from today's $0.7333. That is -1% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Lakewood-Amedex Biotherapeutics, Inc.'s 2032 outlook centres on $0.8698, within a $0.3914 to $1.92 range. That is -4% versus the projected 2031 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2033, LABT could reach as high as $2.82, with a base case around $1.24 and support toward $0.556 — roughly +69% from $0.7333. Buyers look set to stay in control over this stretch.
Expect LABT to range from $0.6529 to $3.34 through 2034. The $1.45 average target implies a +98% move from current prices. That is up +17% on the projected 2033 average. Momentum favours further upside here.
The LABT price prediction for 2035 points to an average of $1.23 (low $0.5545, high $2.83) — a potential gain of +68% on today's $0.7333. Buyers look set to stay in control over this stretch.
In 2040, LABT is projected to trade between $0.7659 and $3.91, averaging $1.70 — a potential gain of +132% from today's $0.7333. That is up +38% on the projected 2035 average. Momentum favours further upside here.
Lakewood-Amedex Biotherapeutics, Inc.'s 2050 outlook centres on $2.40, within a $1.08 to $5.51 range. That is up +41% on the projected 2040 average. That marks a +227% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in LABT today (≈ 1,363.69835 LABT) could be worth
$3,269.84
+$2,269.84 (+227%) by 2050 · US Dollar
Based on the average projected LABT price of $2.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LABTwould be worth at today's price.
$1,000 invested in LABT on Apr 23, 2026 (≈ 115.606942 LABT) would be worth
$84.77
-$915.23 (-91.5%) today · 0.08× · US Dollar
Based on a LABT entry price of $8.65 vs. today's $0.7333.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.75 | $977.73 | -2.2% |
| 1 month ago | $3.66 | $200.36 | -80.0% |
| All time ago | $8.65 | $84.77 | -91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LABT forecast.
Our base-case forecast reaches $1.50 around 2040.
Implied market cap at $1.50: $21.03M
The multi-year forecast shows a bullish trajectory from 2027 onward. By 2027, the average price is projected at $1.05 with a max of $1.76 (min $0.6761). By 2030, the average is $0.8847 with a max of $1.80 (min $0.4305) and an ROI of 25.2.
The 2040 forecast calls for an average of $1.63 with a max of $3.75 (min $0.7331) and an ROI of 130.6. By 2050, the average is $2.34 with a max of $5.38 (min $1.05) and an ROI of 230.8. The sentiment is BULLISH across 2027–2050, indicating a long‑run upside despite near-term uncertainty.
Tap a question to reveal the answer.
In 2030 the average price is $0.8847, with a min of $0.4305 and a max of $1.80, and a forecast ROI of 25.2; sentiment is BULLISH.
The forecast shows a bullish trend starting in 2027 with the average price rising to $1.05 in 2027 and to $2.34 by 2050, with higher max prices along the way. The 2026 value remains at $0.7066 (avg) but near-term risk and uncertainty are noted, so these are estimates, not guarantees.
Yes. The 2040 forecast lists a max price of $3.75, with the average at $1.63 and a bullish sentiment.
Current price is $0.7066 and market cap is $10.12M.
The company changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025.
Lakewood-Amedex Biotherapeutics, Inc. Community Discussion
0Share your Lakewood-Amedex Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.